Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Jade BiosciencesJBIO +1.78%12 3-Year ROIIC % is 0.00 as of Mar. 2026. GuruFocus rates JBIO with a GF Score™ of 12/100. The stock has 1 warning sign investors should review. Among 1,320 Biotechnology companies, Jade Biosciences ranks worse than 75757.5% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Jade Biosciences does not have enough data to calculate 3-Year ROIIC %.
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Jade Biosciences 3-Year ROIIC % Related Terms
Jade Biosciences 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Jade Biosciences's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
JBIO vs NVAX, AVLN, TRAX: 3-Year ROIIC % Comparison
For the Biotechnology subindustry, Jade Biosciences's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jade Biosciences 3-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Jade Biosciences's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Jade Biosciences's 3-Year ROIIC % falls into.
Jade Biosciences's 3-Year ROIIC % for the quarter that ended in is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( () - () )
/
( () - () )
=
/
=
N/A%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Jade Biosciences (JBIO) has a 3-Year ROIIC % of 0.00 as of Mar. 2026. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Jade Biosciences and its competitors. According to the industry distribution chart, Jade Biosciences ranks #999999 out of 1320 companies in the Biotechnology industry.
Is Jade Biosciences' 3-Year ROIIC % too high?
Jade Biosciences' current 3-Year ROIIC % is 0.00. Based on the distribution chart, Jade Biosciences ranks #999999 out of 1320 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Jade Biosciences has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Jade Biosciences' 3-Year ROIIC % compare to NVAX and AVLN?
According to the Biotechnology industry distribution chart, Jade Biosciences ranks #999999 out of 1320 companies for 3-Year ROIIC %. This places Jade Biosciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Jade Biosciences and its competitors. Jade Biosciences's current 3-Year ROIIC % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jade Biosciences stock overvalued right now?
Jade Biosciences (JBIO) has a current 3-Year ROIIC % of 0.00. The current 3-Year ROIIC % is 0.00. Jade Biosciences' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Jade Biosciences (JBIO), the current 3-Year ROIIC % is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Jade Biosciences Inc is a clinical-stage biotechnology company focused on developing therapies for autoimmune diseases. Its flagship candidate, JADE101, targets the cytokine APRIL and is in a Phase 1 clinical trial for the treatment of immunoglobulin A nephropathy. The company's pipeline also includes JADE201, an afucosylated anti-BAFF-R monoclonal antibody, and JADE301, an antibody candidate in preclinical development.
12GF Score
Get the complete analysis for JBIO
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
JBIO has been successfully added to your 
